October 16, 2012 7:35 AM | 1 min read |
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ThresholdPharmaceuticals (NASDAQ: THLD) today announced that the U.S.Food and Drug Administration (FDA) has reached agreement with theU.S. affiliate of Merck KGaA, Darmstadt, Germany, Threshold's partnerfor the development and commercialization of TH-302, covering aSpecial Protocol Assessment (SPA) for a Phase 3 randomized trial ofTH-302 in patients with metastatic or locally advanced unresectablepancreatic cancer. The trial is designed to evaluate the efficacy andsafety of TH-302 in combination with gemcitabine compared withgemcitabine therapy alone. Pursuant to Threshold's license andco-development agreement with Merck, Merck will be responsible forconducting the Phase 3 study under the SPA. A Special Protocol Assessment (SPA) is a written agreement with the
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.